IngredientsPadina pavonica, commonly known as the peacock's tail, is a small brown alga found in the Indian Ocean, the Pacific Ocean, the Atlantic Ocean, and the Mediterranean Sea. It belongs to the domain Eukaryota, within the Stramenopiles, class Phaeophyceae, order Dictyotales, and family Dictyotaceae, genus Padina.
Padina is a genus of brown algae in the family Dictyotaceae (order Dictyotales, class Phaeophyceae), comprising approximately 58 accepted species characterized by their distinctive fan-shaped thalli with involute margins, concentric banding, and calcification using aragonite crystals. Padina pavonica is the type species of the genus.
This species is recorded as Padina pavonia in some texts, and may also be referred to as turkey-feather algae. Due to its fan-shaped thallus, P. pavonica is known also as Peacock's tail and it is commonly found in the Mediterranean Sea.
Padina pavonica, commonly known as peacock's tail, is a marine brown alga (Phaeophyceae) in the family Dictyotaceae, distinguished by its fan- or ear-shaped thallus that reaches up to 15 cm in diameter and features concentric bands of hairs on the lower surface. As the type species of the genus Padina, it is one of only two known calcifying genera among brown algae, precipitating needle-shaped aragonite crystals on its ventral surface that constitute about 11% of its dry weight and provide mechanical support, protection from grazers, and shielding from excess irradiance.
Padina pavonica is a distinctive small brown alga growing to a diameter of up to 10 cm. Young fronds are thin, leafy and flat, with entire margins. Older fronds are thicker, concave, fan-shaped or funnel-shaped, with lobed margins. The outer (under) surface has concentric rows of small, fine hairs and is banded with zones of olive green, pale and dark brown, while the inner (upper) surface is covered with a thin layer of slime. Both sides are thinly calcified and the margins tend to curl inwards.
Padina pavonica exhibits a cosmopolitan distribution across tropical and warm-temperate marine waters, primarily occurring in the Mediterranean Sea where it is abundant, the northeastern Atlantic Ocean from Portugal to the British Isles, the Indo-Pacific region encompassing the Indian Ocean, Red Sea, and various Pacific islands, as well as the Caribbean Sea and Gulf of Mexico.
It inhabits pools in the littoral zone typically with clayey, silty or sandy sediments. Other habitats include rocks and shell fragments in the shallow sublittoral, seagrass meadows, mangrove roots and coral reefs on tidal flats. Padina pavonica is sessile and can tolerate brackish conditions, occurring at depth ranges of 0–20 m.
It is a warmer water species at the northern edge of its range on the south coast of England. This seaweed likes warmer water and is more common further south, for example in the Mediterranean.
In biotechnology, Padina compounds have shown promise in pharmaceuticals, cosmetics, agricultural products, and nanoparticle synthesis. Furthermore, its use in food products is being explored, as it provides a source of nutritional elements and functional ingredients, and is traditionally consumed in different parts of the world. Several species of Padina are being cultivated in Asia — for example, Padina boergesenii in India as a source of alginic acid, mannitol and iodine; P. australis in Indonesia (known locally as agar-agar daun besar) eaten as a salad or collected for preparing gelatin-like sweetmeat; and P. antillarum in Sri Lanka in the fertilizer and animal feed production industry.
As a dietary supplement, Padina pavonica extract is most prominently sold under the proprietary preparation name Dictyolone®. Padina pavonica extract (EPP) is the key ingredient of Dictyol, which is used as a dietary supplement against osteoporosis. In research settings, the extract has been prepared using acetone, methanol, hexane, ethanol, and aqueous solvents, each yielding different phytochemical profiles.
The documented traditional and historical use of Padina pavonica specifically as a medicinal or dietary ingredient is limited in the peer-reviewed literature and remains poorly characterized by authoritative ethnobotanical or pharmacopeial monographs. Its use in food products is being explored, as it provides a source of nutritional elements and functional ingredients, and is traditionally consumed in different parts of the world.
Several species of Padina have been cultivated and used in Asia; for example, P. australis in Indonesia is eaten as a salad or collected for preparing a gelatin-like sweetmeat. The broader genus Padina has a history of food use in coastal communities across the Indo-Pacific and Mediterranean regions, reflecting centuries of human interaction with these accessible intertidal algae, though species-level documentation specific to P. pavonica is sparse.
The available reviewing data collectively highlight the potential of genus Padina as a promising candidate for the development of alternative medicinal agents, and the effective utilisation of this algae as a functional food ingredient, especially in light of its nutritional value, is also warranted.
In terms of modern supplement use, organized commercial exploitation of P. pavonica extract for bone health purposes was pioneered in Malta, where it was processed into a proprietary extract and tested in clinical settings in the 2000s. An application from ICP Ltd. in Malta was submitted to the European Food Safety Authority (EFSA) for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006, related to Padina pavonica extract in Dictyolone® and an increase in bone mineral density.
Regarding the functional and positive influence of P. pavonica on human health, sterols, lipids, polysaccharides, carotenoids, polyphenols, and fibers are the main bioactive compounds found in Padina species. Brown algae are a rich source of compounds and secondary metabolites such as peptides, polyphenols, phytosterols, carotenoids, fatty acids, and polysaccharides.
The Padina pavonica extract (PPE) is especially rich in phenolic compounds, one of the most important classes of natural bioactive compounds: flavonoids and tannins comprised 54.8 mg and 54.4 mg per g of extract, respectively. Hydrocarbons were another major component, with 68.83% corresponding to fatty acids, while sterols represented 8.37% of the extract, including fucosterol and cholesterol.
The total phenolic content varies considerably by geographic source and extraction solvent. Research on Padina pavonica from Portugal found values of 44.61 and 10.48 mg per g of extract when using methanol and dichloromethane, respectively, as extraction solvents.
Fucosterol, the primary sterol found in brown algae, displays numerous advantageous characteristics, incorporating antioxidant and liver-protective qualities, antidiabetic properties, and inhibiting butyrylcholinesterase activity. Fucosterol is particularly concentrated in the hexane fraction of P. pavonica extracts. Fucosterol is the chief sterol found in brown algae during hexane partition and has antioxidant and butyrylcholinesterase inhibitory activities.
Fucoidan has been isolated from Padina pavonica and analyzed for its ash, water, protein, sulfated groups, elemental content, total sugars, and uronic acid levels. Its monosaccharides have been qualitatively and quantitatively determined using high-performance liquid chromatography for fucose detection, which is the main fingerprint of fucoidans. The yields of fucoidan, fucose, and sulfate from P. pavonica were found to be 17.8 ± 0.23%, 34.45%, and 9.52 ± 0.19%, respectively.
This alga is rich in carbohydrates (mainly alginates and laminarans), lipids (fucosterol), vitamins, and mineral salts, and it is known for its slight bioactivity against microbial pathogens.
The fatty acid profile of the extract showed that the presence of saturated fatty acids (SFAs) corresponded to 43.45% of total EPP (63.13% of total FAs). Among these, the most abundant fatty acid was palmitic acid with a total percentage of 34.15%, followed by stearic (3.25%), pentadecanoic (1.95%), arachidic (0.74%), myristic (0.43%), lauric (0.47%), and behenic (0.04%) acids. Monounsaturated fatty acids (MUFAs) made up 23.67% of total EPP (34.40% of total FAs).
Fucosterol and hydroperoxy-24 vinyl-24 cholesterol have been detected in the hexane extract of P. pavonica. Isolated compounds and/or extracts have displayed diverse biological activities such as wound healing for the fucoidan-rich extract of P. tetrastromatica and P. boergesenii, showing considerable improvement in healing signs including angiogenesis, collagen fiber formation, and epidermis formation.
An oxysterol (hydroperoxy-24 vinyl-24 cholesterol) has been identified as being responsible for cytotoxic activity in the KB tumor cell line. The main constituents responsible for antitumoral effects observed in research may include fucosterol, and two terpenoid compounds — dihydroactinidiolide and phytol — of which the acetonic extract of EPP was found to be rich.
P. pavonica precipitates needle-shaped aragonite crystals on its ventral surface that constitute about 11% of its dry weight. This naturally high mineral content, including calcium carbonate in the form of aragonite, has been proposed as a potential contributor to its bone-health-related bioactivity, although this mechanism has not been validated in confirmed human trials (see Section 5.1).
Multiple extraction studies have confirmed measurable radical-scavenging activity in P. pavonica extracts. Ethanolic extracts of P. pavonica harvested from the Red Sea showed DPPH radical inhibition of 77.60%. The highest FRAP (231 µmole Trolox equivalents) and ORAC (55.8 µmole Trolox equivalents) results were reported for ethanolic extracts from Adriatic Sea samples. These activities are attributed primarily to the high phenolic, flavonoid, and tannin content of the extract.
Fucosterol from Padina boryana reduced particulate matter-induced inflammation in RAW 264.7 macrophages by reducing oxidative stress and inflammatory responses, by inhibiting iNOS, COX-2, and pro-inflammatory cytokines and regulating the NF-κB, MAPKs, and Nrf2/HO-1 pathways. Xeniolide-type diterpenoids isolated from P. tetrastomatica revealed significant anti-inflammatory activities in comparison with ibuprofen. These findings derive from closely related Padina species and from in vitro or animal models; direct confirmation in P. pavonica itself in human studies is lacking.
In vitro, the acetonic extract of P. pavonica (EPP) enhanced the expression of earlier differentiation stage markers: a 5.4-fold increase in collagen type I alpha 1 chain (COL1A1), and a 2.3-fold increase in alkaline phosphatase (ALPL), as well as those involved in late differentiation: a 3.7-fold increase in osteocalcin (BGLAP) expression and a 2.8-fold increase in osteoprotegerin (TNFRSF11B). These findings were corroborated by the enhancement in ALPL enzymatic activity (1.7-fold increase) and by the reduction of the RANKL/OPG ratio (0.6-fold decrease). EPP demonstrated the capacity to enhance bone nodule formation by 3.2-fold in 4-week-treated human osteoblasts.
It has been previously shown that seaweed-derived compounds, such as phytosterols, are able to cross the blood-brain barrier and accumulate in the central nervous system (CNS), and may therefore exhibit neuromodulatory and neuroprotective properties. A Padina pavonica extract was exploited to protect mitochondrial membranes against insult by oligomeric aggregates of the amyloidogenic proteins amyloid-β (Aβ), α-synuclein (α-syn) and tau, which are currently considered to be major targets for drug discovery in Alzheimer's disease (AD) and Parkinson's disease (PD). The extract manifested a significant inhibitory effect against swelling of isolated mitochondria exposed to the amyloid oligomers, and attenuated the release of cytochrome c from the mitochondria.
Fucoidan isolated from Padina pavonica demonstrated a promising inhibitory effect on the α-amylase enzyme, reaching 75.69 ± 1.05% inhibition at a concentration of 1000 µg/ml. The study concluded that P. pavonica is an excellent producer of fucoidan, with a significant sulfate content that enhances its biological activities, especially its antidiabetic properties. These findings are from in vitro assays only.
Alginates were detected in P. pavonica collected from coastal waters of Tunisia. Pretreatment of rats with the extracted alginates (25 and 50 mg/kg) displayed a significant decrease in the intensity of gastric mucosal damages compared with a control group, with 64.28% inhibition, while the dose of 200 mg/kg inhibited the gastric lesion area by 90.59%. This evidence is limited to animal models.
Bone health is the area receiving the greatest regulatory and clinical attention for Padina pavonica extract. The most consequential assessment came from the European Food Safety Authority (EFSA).
Following an application from ICP Ltd., the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Padina pavonica extract in Dictyolone® and an increase in bone mineral density. The Panel considered that the Padina pavonica extract in Dictyolone® was sufficiently characterised.
The applicant presented four human intervention studies, four animal studies and two in vitro studies as pertinent to the health claim. No conclusions could be drawn from two of the four human studies as they were carried out with a food that did not comply with the specifications of the food which is the subject of the health claim. The two other human studies did not show an effect of the Padina pavonica extract in Dictyolone® on bone mineral density. The Panel concluded that a cause and effect relationship has not been established between the consumption of Padina pavonica extract in Dictyolone® and an increase (or reduced loss) in bone mineral density.
At the in vitro level, supporting mechanistic data exists. Marine algae have gained much importance in the development of nutraceutical products due to their high content of bioactive compounds. In one study, researchers investigated the activity of Padina pavonica with the aim to demonstrate the pro-osteogenic ability of its extract on human primary osteoblasts (HOb). The data indicated that the acetonic extract of P. pavonica (EPP) is a safe product as it did not show any effect on osteoblast viability. At the same time, EPP showed a beneficial effect on HOb functionality, triggering their differentiation and mineralization abilities.
In a previous in vivo study conducted on 40 postmenopausal women, P. pavonica demonstrated the ability to increase bone mineral density (BMD) and to exert a positive effect on collagen control. However, this study (by Professor Mark Brincat, communicated as proprietary by ICP Ltd.) was not independently published as a peer-reviewed paper at the time of EFSA's review and could not be considered sufficient evidence for a health claim. Based on literature research available at the time of the osteoblast in vitro study (2019), in vitro biochemical and molecular evaluation supporting osteogenic beneficial effects from P. pavonica extracts was described as nonexistent.
Overall evidence strength (bone health): The in vitro osteoblast data is mechanistically interesting but not sufficient on its own. The only regulatory review — by EFSA — found that available human intervention data did not demonstrate a meaningful effect on bone mineral density. Evidence is currently insufficient to support a bone health claim.
An investigation of the antioxidant, antimicrobial and anticancer potential of P. pavonica acetone extracts found a total phenolic content of 26.69 ± 1.86 mg gallic acid equivalent/g, FRAP of 352.82 ± 15.41 µmole Trolox equivalent (TE)/L, DPPH of 52.51 ± 2.81% inhibition, and ORAC of 76.45 ± 1.47 µmole TE/L. These values are established in laboratory (in vitro) assays. Antioxidant activity also showed seasonal variation in field-collected specimens from the Adriatic Sea.
Overall evidence strength (antioxidant): Confirmed in multiple in vitro assays across geographically diverse specimens. No human clinical trials have been conducted to evaluate antioxidant endpoints from P. pavonica supplementation specifically.
Flavonoids extracted from Padina pavonica using microwave-assisted extraction exhibited significant antibacterial activity. Padina fucoidan (PF) showed the largest inhibition zone of 18 mm against Methicillin-Resistant Staphylococcus aureus (MRSA) (ATCC 4330) with a minimum inhibitory concentration (MIC) of 1.25 mg/L. Several Padina species extracts exhibited antiviral activities against HSV and HIV.
Fucoidan from P. pavonica inhibited HSV-1 with an inhibition percentage of 30.89 ± 0.84.
Overall evidence strength (antimicrobial): Findings are limited to in vitro and laboratory settings. No clinical trials in humans have been reported. Results are preliminary.
Researchers have aimed to demonstrate the antitumoral activity of the extract of Padina pavonica (EPP) on human osteosarcoma (OS) cells in order to provide the molecular evidence supporting the development of EPP-based products usable as a potential chemo-preventive agent against OS. The acetonic extract of Padina pavonica (EPP), a brown seaweed collected from French Polynesia, was demonstrated to have a strong pro-apoptotic effect on human OS cells.
Fucosterol, xenicane diterpenes, as well as fucoxanthin displayed antiproliferative activities versus different cancer cell lines. Studies have demonstrated the cytotoxic activity of macroalgae towards different types of cancer cell models, and their consumption has been suggested as a chemo-preventive agent against several cancers such as breast, cervix, and colon cancers.
Overall evidence strength (anticancer): All data are from in vitro cancer cell line experiments. No animal models specific to P. pavonica anticancer effects have been reported in the indexed literature, and no human data exist. Evidence is preliminary and mechanistically exploratory only.
An extract from Padina pavonica (PPE) was exploited as a vital source of natural bioactive compounds to protect mitochondrial membranes against insult by oligomeric aggregates of the amyloidogenic proteins amyloid-β (Aβ), α-synuclein (α-syn) and tau, which are major targets for drug discovery in Alzheimer's disease (AD) and Parkinson's disease (PD). PPE manifested a significant inhibitory effect against swelling of isolated mitochondria exposed to the amyloid oligomers, and attenuated the release of cytochrome c from the mitochondria.
A follow-up study also demonstrated that PPE curtailed the ability of Aβ42 and α-syn monomers to self-assemble into larger β-aggregate structures, as well as potently disrupted their respective amyloid fibrils. The mito-protective and anti-aggregator biological activities of Padina pavonica extract may be of therapeutic value in neurodegenerative proteinopathies, such as AD and PD.
In rodent models, antidepressant-like activity has been investigated. Considering the beneficial effects of P. pavonica, researchers investigated its methanol and hexane partitions (PMP and PHP) in a mouse model. In male mice, depression was initiated by administering dexamethasone (15 µg/kg) subcutaneously. PMP or PHP (80–160 mg/kg) was administered intraperitoneally and all injections continued for two weeks. Different depression criteria were evaluated by forced swim test (FST), marble burying test (MBT), sucrose preference (SP) test, and novelty-suppressed feeding test (NSFT). The hexane partition (PHP) showed an antidepressant-like effect at a lower dose (80 mg/kg) than the methanol partition (PMP) at 160 mg/kg, which could be related to better blood-brain barrier distribution.
Overall evidence strength (neuroprotection/antidepressant): Laboratory and animal model data only. No human clinical evidence exists. Findings are early-stage and hypothesis-generating.
P. arborescens (a closely related Padina species) contains bromophenols reflecting major reports of its antidiabetic effect. For P. pavonica specifically, the antidiabetic mechanism studied most rigorously is α-amylase inhibition by fucoidan. Researchers concluded that Padina pavonica is an excellent producer of fucoidan, with a significant sulfate content that enhances its biological activities, especially its antidiabetic properties. These studies are entirely in vitro; no human data exist for P. pavonica in this area.
Overall evidence strength (antidiabetic): Preliminary in vitro evidence. No clinical trials in humans have been reported.
Alginates detected in P. pavonica had gastroprotective properties in a rat model of gastric mucosal damage, as described in Section 4.6. Overall evidence strength: Animal model only; not evaluated in humans.
The following dosages appear in peer-reviewed research or regulatory submissions; they are reported here only as stated in those sources and do not constitute dosing recommendations.
No established human clinical dosage for Padina pavonica extract supplements has been validated in peer-reviewed literature or approved by a regulatory body such as EFSA, the EMA, or the NIH Office of Dietary Supplements.
Data from the osteoblast differentiation study indicated that the acetonic extract of P. pavonica (EPP) is a safe product as it did not show any effect on osteoblast viability at the concentrations tested. EPP did not exhibit significant effects on human osteoblast viability at the concentrations of 1, 10, and 20 µg/mL after 24-hour treatment. A minor effect was detected only at the highest concentrations tested, and no remarkable toxic effects were observed at the concentrations used.
A documented and source-specific safety concern for Padina pavonica as a dietary ingredient relates to its known capacity to accumulate heavy metals from the marine environment. Maximum limits have been set for heavy metal elements for their content in food and feed by the European Community. In addition, most essential trace elements, like chromium (Cr), cobalt (Co), manganese (Mn), and zinc (Zn), are known to have toxic effects when taken above recommended levels.
Research specifically on P. pavonica from the northern Adriatic Sea has investigated spatial and temporal distribution of trace elements in the alga, and Padina pavonica has been identified in the scientific literature as a useful bioindicator organism for monitoring marine heavy metal pollution — a characteristic that simultaneously underscores its bioaccumulation capacity. P. pavonica is used above all as a sensor or marker to study pollution levels in the sea and, in general, in the marine environment. This means that harvest location and water quality are critical safety variables for any supplement derived from wild-collected specimens.
The two human studies reviewed by EFSA did not show an effect of the Padina pavonica extract in Dictyolone® on bone mineral density. The Panel concluded that a cause and effect relationship has not been established between the consumption of Padina pavonica extract in Dictyolone® and an increase (or reduced loss) in bone mineral density. This means that, as of the EFSA review, no health claim for P. pavonica extract on bone mineral density is authorised under EU Regulation No 1924/2006.
No long-term human clinical trials or systematic safety reviews specific to Padina pavonica supplementation have been published in the indexed literature. The overall evidence base is dominated by in vitro experiments and a small number of animal studies. Drug interaction data for P. pavonica extracts in humans are not available in the peer-reviewed literature. The fucoidan component, based on research in other species, is known to have anticoagulant properties, which is a class-level consideration for sulfated polysaccharide-containing algal supplements generally.
Health conditions that Peacock's tail may help support.
Body systems that Peacock's tail may help support.
Go back